<DOC>
	<DOCNO>NCT00006044</DOCNO>
	<brief_summary>RATIONALE : High dos testosterone may effective kill prostate cancer cell longer respond hormone therapy . PURPOSE : Phase I trial study effectiveness testosterone treat patient progressive prostate cancer long respond hormone therapy .</brief_summary>
	<brief_title>Testosterone Treating Patients With Progressive Prostate Cancer That No Longer Responds Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety maximum tolerate dose exogenously administer testosterone patient progressive androgen-independent prostate cancer castrate state either surgically pharmacologically minimum 1 year . - Assess change expression androgen receptor receptor human biopsy specimen circulate tumor cell treatment patient population . OUTLINE : This dose-escalation study . Patients receive testosterone via enhanced absorption transdermal system continuously 28 day . The transdermal patch change daily . Cohorts 3-6 patient receive fix daily dose testosterone escalate duration exposure maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow day 1 week 2 4 . PROJECTED ACCRUAL : A total 3-18 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm androgen independent metastatic prostate cancer Progressive disease manifest either : New osseous lesion bone scan great 25 % increase bidimensionally measurable soft tissue disease appearance new site disease MRI CT scan OR Minimum 3 rise PSA value baseline obtain 1 week apart , 2 rise PSA value 1 month apart , percentage increase range value least 25 % Castrate state orchiectomy gonadotropinreleasing hormone analogue minimum 1 year Testosterone great 30 ng/mL Measurable disease Metastatic disease bone scan , MRI , CT scan Rising PSA value If receive antiandrogen therapy , must show progressive disease treatment No active CNS epidural tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT le 3 time upper limit normal PTT le 14 second Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV cardiac disease Pulmonary : No severe debilitate pulmonary disease Other : No infection require IV antibiotic No severe medical problem would increase risk toxicity PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior biologic therapy No concurrent immunotherapy Chemotherapy : Recovered prior chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics If prior orchiectomy , must continue gonadotropinreleasing hormone analog maintain castrate level testosterone No concurrent finasteride No concurrent hormonal therapy Radiotherapy : Recovered prior radiotherapy No concurrent radiotherapy indicator lesion Surgery : See Disease Characteristics Recovered prior surgery No concurrent surgery measurable lesion Other : At least 4 week since prior investigational anticancer drug recover No concurrent investigational anticancer agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>